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ABSTRACT 
Objective: To evaluate erythropoietin-producing hepatocellular carcinoma (Eph) / Eph 
receptor-interaction protein (ephrin) expression in oral squamous cell carcinoma 
(OSCC) and oral epithelial precursor lesions (OEPLs), EphA2, EphB4, and ephrinB2 
were examined and compared with microvessel density (MVD) and lymphatic vessel 
density (LVD). 
Methods: Samples from 73 OSCC and 43 OEPLs patients were immunohistochemically 
analyzed with antibodies against EphA2, EphB4, ephrinB2, CD34, and D2-40. Results 
were compared with clinicopathological findings. 
Results: Immunohistochemical reactivity for EphA2, EphB4, and ephrinB2 was 
detected in epithelial cells and some stromal vascular cells in OEPLs and OSCC, 
proportionately with the level of malignancy. Blood vessel endothelial cells stained with 
CD34 and lymphatic vessel endothelial cells stained with D2-40 were up-regulated in 
OEPLs and OSCC. In OSCC, ephrinB2 and EphB4 exhibited significant correlation 
with recurrence and invasion depth, respectively. MVD was significantly lower in slight 
lymphocytic reaction than in prominent stromal reaction. Correlation was found 
between LVD and T classification, postoperative metastasis, survival, mode of invasion, 
and invasion depth. 
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Conclusion: Expression of EphA2, EphB4, ephrinB2, MVD, and LVD might be 
associated with malignant potential of the oral epithelium. Angiogenesis and 
lymphangiogenesis appear to be related to progression of potentially malignant oral 
lesions. 
 
Keywords  
Eph/ephrin, oral squamous cell carcinomas, oral epithelial precursor lesions, 
angiogenesis, lymphangiogenesis 
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INTRODUCTION 
Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral 
cavity, it occurs predominantly in the fifth and sixth decades, and is typically associated 
with risk factors, such as smoking, alcohol, and human papilloma virus (HPV) infection. 
Worldwide, OSCC incidence is higher among males than females. OSCC may arise in 
any part of the oral cavity, including the tongue, gingiva, palate, buccal mucosa, floor of 
the mouth, and lip, thus indicating differences in disease occurrence (Warnakulasuriya, 
2009; Kouketsu et al., 2016; Takata et al., 2017). Other features include rapid growth, 
diffuse invasion, cervical lymph node metastasis, and other distant organ metastases, 
most commonly into the lungs. Radical surgery of the primary tumor with or without 
chemoradiotherapy is the standard treatment for OSCC. In most countries, five-year 
survival rates for OSCC are around 50% (Warnakulasuriya, 2009). Oral epithelial 
precursor lesions (OEPLs) represent morphologically altered tissues that possess a 
greater risk of malignant transformation than normal tissues; leukoplakia, in particular, 
is a well-known precursor lesion. Leukoplakia is considered a potentially malignant 
disorder, and use of the clinical term cannot rule out the presence or absence of 
histopathological features of epithelial dysplasia. The World Health Organization 
(WHO) defines epithelial dysplasia at this body site as comprising of a spectrum of 
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architectural and cytological epithelial changes caused by an accumulation of genetic 
changes that can be associated with an increased likelihood of progression to squamous 
cell carcinoma. The 2017 WHO classification divides precursor lesions into low-grade 
and high-grade dysplasia (Gale et al., 2017; Takata et al., 2017). 
Tumor angiogenesis plays a critical role in both local growth and systemic 
dissemination of malignancies (O’Reilly et al., 1997). Angiogenesis is characterized by 
complex mechanisms involving vascular endothelial growth factor (VEGF), 
angiopoietin, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) 
(Kumamoto et al., 2002; Bergers et al., 2003). In addition, the lymphatic system also 
contributes to tumor cell dissemination. Indeed, regional lymph nodes metastasis is an 
early event in systemic extension of the disease. Lymphangiogenesis is also driven by 
complex mechanisms associated with VEGF-C, D, PDGF-BB，FGF-2，angiopoietin-1，
and  hepatocyte growth factor (HGF) (Kubo et al., 2002; Cao et al., 2004; Morisada et 
al., 2005; Saito et al., 2006). Cervical lymph node metastasis is considered an important 
prognostic factor for patients with OSCC (Warnakulasuriya, 2009; Kreppel et al., 2010). 
According to previous studies, angiogenesis and lymphangiogenesis are essential 
processes within the tumor growth processes (Bunget et al., 2013). In OSCC, VEGF is 
related to angiogenesis (Shao et al., 2008), and the VEGF‑C/ VEGF receptor (VEGFR) 
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‑3 axis is associated with lymph node metastasis through lymphangiogenesis (Naruse et 
al., 2015).  
Erythropoietin-producing hepatocellular carcinoma (Eph) receptors, a class of 
endothelial receptor tyrosine kinases, have been implicated in the control of blood 
vessel formation. The ligands of Eph receptors, called Eph receptor-interaction proteins 
(ephrins) are bind to the receptors on the cell membrane. Each Eph receptor and its 
ephrin ligand is divided into A and B subclasses based on sequence homology and 
binding affinities (Gale et al., 1999; Holder et al., 1999). Eph receptor-ephrin signaling 
has been implicated in many processes, including embryonic development and human 
diseases (Pasquale et al., 2005). EphrinA1 and Eph receptor A2 (EphA2) are associated 
with tumor vasculature in several cancers (Ogawa et al., 2000; Kataoka et al., 2004). 
Overexpression of EphA2 is related to malignancy in tongue squamous cell carcinoma 
(Shao et al., 2008). In contrast, endothelial cell expression of Eph receptor B4 (EphB4) 
indicates that vascular development is mediated by ephrinB2 signaling (Wang et al., 
1998). Overexpression of EphB4 and ephrinB2 has been described in papillary thyroid 
cancer, uterine cervical cancer, and urogenital cancer (Alam et al., 2009; Ozgür et al., 
2011; Sharma et al., 2015). In addition, EphB4 and ephrinB2 are involved in the 
formation of both blood and lymphatic vessels under normal and pathologic conditions. 
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Systemic administration of ephrinB2-blocking antibodies caused a drastic reduction in 
the number of blood and lymphatic vessels in xenografted mice and a concomitant 
reduction in tumor growth (Abéngozar et al., 2012). However, to our knowledge, the 
expression of EphA2, EphB4, and ephrinB2, as well as their relationship, during 
angiogenesis and lymphangiogenesis in OSCC remain poorly understood.  
The aim of this study was to use immunohistochemistry to investigate the expression 
of EphA2, EphB4, and ephrinB2 in OSCC and OEPLs, and determine if there was a 
correlation with angiogenesis and lymphangiogenesis. Moreover, the finding were 
compared with clinicopathological features of patients with OSCC. 
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MATERIALS AND METHODS 
The study protocol was reviewed and approved by the Research Ethics Committee of 
Tohoku University Graduate School of Dentistry (26-52). 
 
Tissue preparation 
Specimens were surgically removed from 73 patients with primary OSCC and 43 
patients with OEPLs at the Department of Oral and Maxillofacial Surgery, Tohoku 
University Hospital, between 2010 and 2013. None of the OSCC patients had received 
any chemotherapy or radiotherapy before excision. Ages ranged from 33 to 93 years 
(mean, 68 years). Thirty three patients were men and 40 were women. Forty-two 
carcinomas were located in the tongue, 7 in the upper gingiva, 9 in the lower gingiva, 3 
in the lower lip, 1 in the palate, 8 in the buccal mucosa, and 3 in the floor of the mouth. 
The TNM disease stage was classified according to the Union for International Cancer 
Control (UICC) system (Brierley et al., 2017). Patients were classified as: T1 (27 cases), 
T2 (24), T3 (6), and T4 (16); N0 (54 cases), N1 (8), N2 (10), and N3 (1); and M0 (70 
cases), and M1 (3). During follow-up, 17 patients had local recurrence, and 9 had 
postoperative metastasis (regional lymph node metastasis in 5 patients and pulmonary 
metastasis in 4). Five patients died of OSCC, and 6 patients died of another disease. 
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None of the OEPLs patients was diagnosed as OSCC at any site before surgery. OEPLs 
patients (21 men and 22 women) were aged between 30 and 89 years (mean, 68 years); 
16 OEPLs were located in the tongue, 3 in the upper gingiva, 15 in the lower gingiva, 2 
in the hard palate, 6 in the buccal mucosa, and 1 in the oral floor. Two patients had local 
recurrence, and 8 had cancerization from OEPLs to OSCC. Ten samples of normal 
mucosa at distant points from the excised neoplastic tissues were used as controls.  
Tissue samples were fixed in 10% buffered formalin for several days, and embedded 
in paraffin. Tissue blocks were sliced into 4μm-thick sections for routine histological 
examination and subsequent immunohistochemical analyses. OSCC samples were 
classified into 54 well differentiated types and 19 moderately differentiated types, 
according to the WHO classification of tumors of the oral cavity and mobile tongue 
(El-Naggar et al., 2017). The degree of stromal lymphocytic reaction was classified as 
slight for 4 specimens, moderate for 64, and severe for 5. The mode of invasion was 
classified according to Yamamoto et al. (Yamamoto et al., 1984), and the carcinoma 
grade was 2 for 18 specimens, 3 for 43, 4C for 9, and 4D for 3. Invasion depth was 
defined as microinvasion (6 specimens), invasion within mucosal tissue (30), and 
invasion into submucosal tissue (37). The OEPLs pathological diagnosis was made 
according to the WHO classification of tumors of the oral cavity and mobile tongue 
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(Gale et al., 2017; Takata et al., 2017). Fourteen patients had leukoplakia without 
epithelial dysplasia (hyperplasia; LP), 15 had low-grade epithelial dysplasia (mild to 
moderate dysplasia; LD), and 14 had high-grade epithelial dysplasia (severe dysplasia 
or carcinoma in situ; HD). 
 
Immunohistochemistry 
Immunohistochemical studies were done using the following primary antibodies: 
rabbit anti-EphA2 polyclonal antibody (1:50; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), rabbit anti-EphB4 polyclonal antibody (1:100; Proteintech, Rosemont, IL, 
USA), rabbit anti-EphrinB2 polyclonal antibody (1:50; Santa Cruz Biotechnology), 
mouse anti-CD34 monoclonal antibody (prediluted; Nichirei, Tokyo, Japan; subclass 
IgG1) and mouse anti-D2-40 monoclonal antibody (prediluted; Biolegend, San Diego, 
CA, USA; subclass IgG1). Tissue sections were deparaffinized and immersed in 
methanol with 3% hydrogen peroxide. Specimens for EphA2, EphB4, and ehprinB2 
analyses were heated in 0.01 M citrate buffer (pH 6.0) for 10 min by autoclave (121°C, 
202 kPa). Then, sections were incubated with primary antibodies at 4°C overnight. 
These sections were allowed to react with peroxidase-conjugated anti-rabbit or mouse 
IgG polyclonal antibody (Histofine SimpleStain MAX-PO, Nichirei) for 45 min, and the 
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reaction products were visualized by immersing the sections in 0.03% diaminobenzidine 
(DAB) solution containing 2mM hydrogen peroxide for 3 min. Nuclei were lightly 
stained with Mayer’s hematoxylin. For control studies of the antibodies, serial 
tissue sections were treated with phosphate-buffered saline (PBS), normal 
rabbit IgG, and mouse anti-desmin monoclonal antibody (Nichirei; subclass 
IgG1) instead of primary antibodies was confirmed to be unstained. 
 
Evaluation of staining for EphA2, EphB4, and ephrinB2  
Immunohistochemical reactivity for EphA2, EphB4, and ephrinB2 was evaluated and 
classified into three groups: (-) negative, (+) positive (reactive at the same level as 
adjacent normal part), and (++) strongly positive (strongly reactive as compared with 
adjacent normal part). 
 
Microvessel density (MVD) and lymphatic vessel density (LVD) determination 
MVD and LVD were estimated using CD34-positive blood vessel endothelial cells 
and D2-40-positive lymphatic endothelial cells, respectively. After scanning 5 areas 
displaying the highest neovascularization (vascular hotspots) in subepithelial 
mesenchymal tissue or tumor stromal tissue at 20-fold magnification, the number of 
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CD34-positive blood vessels and D2-40-positive lymphatic vessels in the hotspots were 
counted at 200-fold magnification, and the average count was recorded as MVD and 
LVD for each case. Based on the criteria of Weidner et al. (Weidner et al., 1991), 
highlighted endothelial cells or a cell cluster clearly separated from adjacent 
microvessels, epithelial cells, and other connective tissue elements were regarded as 
distinct countable microvessels. The presence of a lumen or red blood cells was not 
required, and single cell sprouts were included in the counts. 
 
Statistical analysis 
Statistically significant differences between the percentages of cases with EphA2, 
EphB4, and ephrinB2 reactivity, as well as differences between mean values of MVD 
and LVD were analyzed by the Mann-Whitney U-test for differences between two 
groups or the Kruskal-Wallis H-test for differences among three or more groups. 
P-values of less than 0.05 were considered to indicate statistical significance. 
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RESULTS 
Immunohistochemical reactivity for EphA2, EphB4, ephrinB2, CD34, and D2-40 in 
normal mucosa, LP, LD, HD, and OSCC 
 
Expression of EphA2, EphB4, and ephrinB2 was detected in the cell membrane and 
cytoplasm of epithelial cells and some stromal vascular endothelial cells (Fig1: A1-6, 
B1-6, C1-6). In normal mucosa, LP, and LD, EphA2 was detected in epithelial cells 
except for the superficial layer (Fig1: A1 -3); whereas EphB4 was detected in epithelial 
cells near the basement membrane (Fig1: B1 -3, C1 -3). HD exhibited stronger 
reactivity for EphA2, EphB4, and ephrinB2 in dysplastic cells than in normal cells 
(Fig1: A4, B4, C4). In OSCC, EphA2, EphB4, and ephrinB2 were expressed in 
carcinoma cells except for keratinized areas (Fig1: A5 -6, B5 -6, C5 -6). 
The results of immunohistochemical analyses for EphA2, EphB4, and ephrinB2 in 
normal mucosa, LP, LD, HD, and OSCC are summarized in Table1. EphA2 
immunoreactivity was significantly lower in normal mucosa than in HD (P < 0.01) and 
OSCC (P < 0.001). EphA2 reactivity was significantly lower in LP than in LD (P < 
0.05), HD (P < 0.01), or OSCC (P < 0.001). EphB4 immunoreactivity was significantly 
lower in normal mucosa than in HD (P < 0.05) or OSCC (P < 0.001), in LP compared to 
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HD (P < 0.01) or OSCC (P < 0.001), and in LD compared to HD (P < 0.05) or OSCC 
(P < 0.001). EphrinB2 immunoreactivity was significantly higher in OSCC than in 
normal mucosa, LP, or LD (P < 0.001, respectively).  
Positive staining for CD34was observed in blood vessel endothelial cells of normal 
mucosa, LP, LD, HD, or SCC (Fig1: D1 -6). MVD was significantly higher in OSCC 
than in normal mucosa (P < 0.05), LP (P < 0.01), LD (P < 0.01), or HD (P < 0.05) 
(Table1). Positive staining for D2-40 was observed in lymphatic endothelial cells and 
epithelial cells neighboring the basement membrane of normal mucosa, LP, LD, HD, 
and SCC (Fig1: E1 -6). LVD was significantly lower in normal mucosa than in HD (P < 
0.05) or OSCC (P < 0.001) (Table1), but significantly higher in OSCC than in LP (P < 
0.001) or LD (P < 0.05) (Table1).  
 
Correlation between clinicopathological variables and the results of 
immunohistochemical analysis in OSCC 
EphrinB2 immunoreactivity was significantly higher in patients without recurrence 
than in those with recurrence (P < 0.05). LVD was significantly higher in T1 than in T3 
(P < 0.05) or T4 cases (P < 0.01), whereas T2 cases showed significantly higher LVD 
than T4 cases (P < 0.01). LVD was significantly higher in patients without 
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postoperative metastasis and surviving cases than in patients with postoperative 
metastasis and dead cases (P < 0.01, respectively) (Table 2).  
EphB4 immunoreactivity was significantly higher in cases invaded into submucosal 
tissue than in those showing intramucosal invasion (P < 0.05). MVD was significantly 
lower in slight stromal lymphocytic reaction than in moderate and severe stromal 
lymphocytic reaction (P < 0.05, respectively). LVD was significantly higher in mode of 
invasion grade 2 cases than in mode of invasion grade 3 or 4C cases (P < 0.05, 
respectively). Finally, LVD was significantly higher in cases with microinvasion than in 
those with submucosal invasion (P < 0.01) (Table3). 
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DISCUSSION 
OEPLs and OSCC develop as a result of increased genetic instability that manifests 
through stimulation of oncogenes and switching off of tumor suppressor genes. 
Increased malignant potential in the oral epithelium is characterized by loss of cellular 
control systems that regulate cell cycle progression, pitting cell death against growth 
imbalance, as well as inadequate parenchymal-stromal interaction, abnormal 
angiogenesis and/or lymphangiogenesis. These aberrations cause a variety of poor 
prognosis (Khan et al., 2009). In the present study, we immunohistochemically 
examined angiogenesis- and/or lymphangiogenesis-related factors, EphA2, EphB4, and 
ephrinB2 in 43 cases of OEPLs and 73 cases of OSCC. Their expression was compared 
with tumor angiogenesis and lymphangiogenesis. In previous studies, EphA2 was found 
to be overexpressed in tongue and colorectal cancer (Kataoka et al., 2004; Shao et al., 
2008), whereas overexpression of EphB4 and ephrinB2 was reported in papillary 
thyroid, uterine cervical, and urogenital cancer (Alam et al., 2009; Ozgür et al., 2011; 
Sharma et al., 2015). In our study, EphA2, EphB4, and ephrinB2 were detected chiefly 
in epithelial cells in OEPLs and OSCC, and their expression increased according to the 
level of malignancy, especially in HD and OSCC. These results suggest that 
angiogenetic and/or lymphangiogenetic factors EphA2, EphB4, and ephrinB2 might be 
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associated with the malignant potential of the oral epithelium. Moreover, our study 
reports increased angiogenesis in OSCC, and lymphangiogenesis in OSCC and 
epithelial dysplasia. Previous studies have reported higher numbers of blood vessel 
endothelial cells stained with CD34 and lymphatic vessel endothelial cells stained with 
D2-40 in stromal tissue of colon and breast cancer (Lai et al., 2014; Planeix et al., 2015). 
Angiogenesis and lymphangiogenesis in oral potentially malignant lesions are regarded 
as key components in tumor multistep progression. In addition, our present study 
suggests that EphA2, EphB4, and ephrinB2 expression is implicated in not only 
angiogenesis but also lymphangiogenesis. 
Correlation analyses with clinical variables, such as age, sex, and site, in OSCC 
patients indicated no apparent association with EphA2, EphB4, and ephrinB2 
immunoreactivity, MVD, and LVD. However, EphB4 and ephrinB2 tended to increase 
in grade 3 and 4 T-classified tumors; whereas EphA2, EphB4 and ephrinB2 expression 
tended to increase in metastatic cases in N and M tumors, suggesting that a higher TNM 
staging coincides with increased expression of these factors in OSCC. Our date show 
that ephrinB2 immunoreactivity was significantly higher in patients without recurrence 
than in those with recurrence; whereas the opposite was true for EphA2 and EphB4. 
Also, expression of EphA2, EphB4, and ephrinB2 was slightly greater in postoperative 
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metastasis-positive cases and patients who died of OSCC. These findings suggest that 
EphA2, EphB4, and ephrinB2 expression in OSCC is a poor prognostic marker. Even 
though MVD was slightly higher in T3 cases, no other association with clinical 
variables was detected in our study. In contrast, LVD inversely correlated with 
progression of TNM classification, postoperative metastasis, or patient survival. A 
previous study has demonstrated higher LVD in T3/T4 than in T1/T2 cases (Miyahara 
et al., 2007), whereas another report has showed decrease in LVD according to T and N 
classification (Watanabe et al., 2013). The exact reasons for these discrepancies remain 
to be determined; however, at present, advanced OSCC cases might suppress 
lymphangiogenesis rather than activate it. 
Additionally, in correlation analyses with pathological variables, expression of 
EphA2, EphB4, and ephrinB2 tended to increase in moderately differentiated OSCC 
compared with well-differentiated cases, suggesting that differentiation of OSCC cells 
might be affected by these factors. Also, our findings indicate that MVD and LVD 
tended to be low in cases with slight stromal lymphocytic reaction compared with those 
with marked stromal reaction. High MVD and LVD values have been suggested to 
reflect interaction with their stromal tissues in OSCC (Miyahara et al., 2007). Moreover, 
EphA2, EphB4, and ephrinB2 expression was found to increase slightly in 4C and 4D 
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cases in the OSCC mode of invasion. EphB4 immunoreactivity was significantly higher 
in patients with submucosal invasion than in those with mucosal invasion. Moreover, 
both EphA2 and ephrinB2 tended to increase in submucosal invasive cases compared 
with mucosal invasive one. The above features suggest that these vascular related 
factors affect invasion mode and/or growth in OSCC. At the same time, LVD was 
significantly lower in grade 3 and 4C patients than in grade 2 patients, as well as in 
patients with submucosal invasion than in those with intramucosal invasion. These 
findings suggest that the number of lymph vessels in the tumor microenvironment is 
affected by repeated destruction and regeneration associated with the advanced invasion 
of cancer cells (Nakaya et al., 2005; Goes et al., 2012; Agarwal et al., 2014).  
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FIGURE CAPTIONS 
Fig. 1.2. Immunohistochemical reactivity for EphA2 (A1 -6), EphB4 (B1 -6), ephrinB2 
(C1 -6), CD34 (D1 -6), and D2-40 (E1 -6) in normal mucosa, leukoplakia (LP), 
low-grade dysplasia (LD), high-grade dysplasia (HD), and oral squamous cell 
carcinoma (well-differentiated squamous cell carcinoma: WSCC; moderate 
differentiated squamous cell carcinoma: MSCC). 
EphA2, EphB4, and ephrinB2 staining showing membranous and cytoplasmic reactivity 
in epithelial cells and some stromal vascular endothelial cells (A1 -6, B1 -6, C1 -6).  
Normal mucosa, LP, and LD showing EphA2 reactivity in epithelial cells except for the 
superficial layer (A1 -3).  
Normal mucosa, LP, and LD showing EphB4 and ephrinB2 reactivity in epithelial cells 
near the basement membrane (B1 -3, C1 -3).  
HD showing stronger reactivity for EphA2, EphB4, and ephrinB2 in dysplastic cells 
than in normal cells (A4, B4, C4).  
Oral SCC showing reactivity for EphA2, EphB4, and ephrinB2 in most carcinoma cells 
except for keratinized areas (A5 -6, B5 -6, C5 -6).  
Positive staining for CD34 found in blood vessel endothelial cells of normal mucosa, LP, 
LD, HD, and oral SCC (D1 -6).  
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Positive staining for D2-40 found in lymphatic endothelial cells and epithelial cells 
neighboring the basement membrane of normal mucosa, LP, LD, HD, and oral SCC (E1 
-6). 
A1~E1, A2~E2, C3~E3, D4, E4, D5, E5, B6, D6, E6: × 200 
A3, B3, A4~C4, B5, A6, C6: × 100 
A5, C5: × 40 
 
Fig. 1  
Fig. 2  
Table1：Immunohistochemical reactivity for Eph/ephrin and vessel densities in oral epithelial precursor lesions and squamous cell carcinoma
MVD LVD
- + ++ - + ++ - + ++
* ** * *
** *** ** *** *** * ***
*** * *** *** ** ***
*** *** ** *
*
Immunoreactivity
 (-): negative 
 (+): positive (reactive at the same level as adjacent  normal part)
 (++): strongly positive (strongly reactive as compared with adjacent normal part)
MVD
 Microvessel density
LVD
 Lymphatic vessel density
Statistical significance
 *P＜0.05
 **P＜0.01
 ***P＜0.001
Number of
cases
ephrin B2EphB4EphA2
14 2(14.3%) 11(78.6%) 1(7.1%)
0(0%) 0(0%)
Squamous cell carcinoma (SCC) 73 1(1.4%) 5(6.9%) 67(91.8%)
8(53.3%)
14 0(0%) 4(28.6%)
Normal mucosa 10 0(0%) 10(100%) 0(0%)
Leukoplakia without epithelial dysplasia (LP)
Low-grade epithelial dysplasia (LD)
High-grade epithelial dysplasia (HD)
15 0(0%) 7(46.7%)
13.40±1.02
10(71.4%)
0(0%)
0(0%)
0(0%)
0(0%)
1(6.7%)
9(64.3%)
12(85.7%)
14(93.3%)
7(50.0%)
0(0%) 0(0%) 10(100%) 51.40±11.2910(100%)
0(0%)
14(100%)
14(93.3%)
5(35.7%)
12(16.4%)61(83.6%)
1(7.1%)
0(0%)
0(0%)
1(1.4%) 12(16.4%)
14.50±3.56
19.13±4.13
21.64±6.04
26.12±7.98
1(7.1%)
1(6.7%)
7(50.0%)
60(82.2%)
51.64±18.86
53.40±14.82
54.93±15.35
70.66±16.53
＊
＊
Table2：Correlation between clinical variables, immunoreactivity for Eph/ephrin and vessel densities in oral squamous cell carcinoma
MVD LVD
   -     +    ++    -      +    ++    -      + ++
*
**
**
*
**
**
Immunoreactivity
 (-): negative 
 (+): positive (reactive at the same level as adjacent  normal part)
 (++): strongly positive (strongly reactive as compared with adjacent normal part)
MVD
 Microvessel density
LVD
 Lymphatic vessel density
Statistical significance
 *P＜0.05
 **P＜0.01
 P =0.188901
P =0.001474
P =0.02253
P =0.01946
P =0.289022
P =0.5
Number of
cases P  value P  value P  value P  valueP  value
P =0.808402
P =0.16872
P =0.317428
P =0.152192
P =0.173916
P =0.343423
P =0.486979
P =0.16511
P =0.097499
P =0.55158
P =0.71814
P =0.251434
P =0.647871
P =0.495573
P =0.529798
P =0.016913
P =0.052066
P =0.077978
P =0.35922
P =0.309871
P =0.25968
98.00 25.00
25.80±7.591 6 49 70.73±17.22
15.57±8.09
15.63±9.51
21.67±5.56
7
1
58
2
0
P =0.281165
P =0.328412
EphA2 EphB4
0
0
11
1
1
0
0
0
0
0
1
P =0.32412
34
7
43
8
0
0
8
3
ephrin B2
P =0.88113 P =0.83729
P =0.064347
P =0.46314
P =0.268601
P =0.93466
Survival
Age
Sex
Site
T classification
N classification
M classification
Recurrence
Postoperative metastasis
Negative 56 0 4 52 0 10 46
27.18±9.07
27.19±7.69
18.56±5.60
27.24±7.64
19.82±6.87
Positive 17 1 1 15 0 2 15 0 6 11 70.41±14.02
71.22±14.684 59 0
0 1 8 1 8
1 11 52
57
10
0
0
11
1
11 53
8
P =0.382234
P =0.467727 P =0.243045
Negative 64 1
51
9
51
10
1
0
10
2
Alive
Dead
62
11
1
0
4
1
Positive 9 0 1 0 66.67±25.83
71.53±15.42
65.73±21.09
29.00
70.49±16.46
74.67±17.75
26.39±7.99
20.00±4.55
59
2
1
0
11
1
68.30±17.08
8
1 18.26±5.85
21.90±6.56
45
7
27.61±8.0271.85±15.46
62.13±21.50
0
3
0
0
1
70
3
1
0
5
0
64
3
2
3
P =0.217955
10
1
9
1
10
1
0
0
0
1
4
2
1
0
49
6
11
0
54
8
1
0
1
2
27.71±7.72
21.67±7.39
21.81±6.71
0
3
1
P =0.44994
20
21
28.26±7.64
5
14
1
1
82.33±18.60
64.00±18.48
0
0
71.26±13.66
71.50±15.58
8
2
1
0
6
3
P =0.12725
3
4
27
24
6
16
19
22
5
15
6
13
0
0
0
0
0
0
1
2
0
1
26
22
24.33±8.81
1
6
2
72.98±27.90
68.14±25.14
62.00±14.28
68.67±13.60
74.13±21.92
59.00±8.83
82.00
35
7
7
2
22.00
24.50±5.89
24.33±6.02
P =0.78099
7
0
2
1
0
1
1
0
0
0
0
0
1
0
1
5
3
8
0
1
0
0
3
0
0
0
0
0
0
0
0
38
6
8
3
1
8
3
3
1
1
0
0
0
0
1
0
0
0
0
0
0
Palate
Buccal mucosa
Floor of mouth
42
7
9
3
1
8
3
Tongue
Upper gingiva
Lower gingiva
Lower lip
31
68.36±25.76
72.55±26.43
15.73±7.93
16.94±8.01
30
31
0
1
4
8
P =0.121174
21.54±6.17
M
F
33
40
0
1
2
3
31
36
0
0
3
9
11
1
0
0
2
0
11
1
29
29.12±6.790 2
3 0 0 3 28.00±2.94
16.69±8.535 16 1 4 16 66.71±26.430
22 0 5 20 71.32±13.30 25.36±8.530 3
0
0
2
3
1 1 75.00±7.00 32.00±9.00
76.67±20.170 0
0 0 2 0
P =0.59412
8
25
21
13
1
2
3
0
0
30-39
40-49
7
24
18
12
1
0
0
0
0
1
0
0
1
1
2
1
0
50-59
60-69
70-79
80-89
90-99
2
0
6 0 0 8 76.50±13.85
70.62±23.69
64.00
＊
Table3：Correlation between pathological variables, immunoreactivity for Eph/ephrin, and vessel densities in oral squamous cell carcinoma
MVD LVD
   -     +    ++    -      +    ++    -      +    ++
*
*
*
*
**
*
Immunoreactivity
 (-): negative 
 (+): positive (reactive at the same level as adjacent  normal part)
 (++): strongly positive (strongly reactive as compared with adjacent normal part)
MVD
 Microvessel density
LVD
 Lymphatic vessel density
Statistical significance
 *P＜0.05
 **P＜0.01
21
0 1 5 0 0 6
Submucosal 37 0 1 36
Mucosal tissue 30 1 3 26
74.40±8.48
13
37 0
5
Microinvasion
40
8
3
0
0
0
18
43
9
3 0
2 0 16
6 0 1 5
2
8
0 11 53 1
0 4 0
1 4 0 2
1
0
6
1
68.27±16.71 23.84±7.420 2 35 0 4 33
1 8 21 73.30±16.71 27.40±7.95
0
8
3
72.17±11.62 33.83±4.49
P=0.05975
0 9
5
Moderate 64 1 4 59
1
0
Well 54 1 4 49 0
Slight 4 0 1 3 0
10 43
10 53
2
43
Moderate 19 0 1 18 0 1 18
0 4
11
0
26.81±8.03
24.16±7.49
30.33±7.60
25.16±7.43
21.33±6.93
29.00±8.52
15
35
7
3
73.33±13.24
72.56±17.41
58.33±13.00
64.33±12.55
45.50±7.09
17
P=0.86098
P=0.29511
P=0.166981
71.94±16.15 26.64±7.86
17.00±5.15
26.80±6.913
P  value P  value
Invasion depth
70.37±15.51
71.47±19.11
0
0
2
1
0
2
2
1
00
Degree of defferentiation
Mode of invasion
3
4C
4D
Severe 5 0 0
P  value P  value
P=0.099611
P=0.069655
P=0.03367
P=0.00823
Stromal lymphocytic reaction
EphA2 EphB4 ephrin B2
P  value
P=0.294106
P=0.3935
P=0.89568
P=0.21421
P=0.393413
P=0.01637
P=0.091728
P=0.430046
Number
of cases
P=0.065797
P=0.65461
P=0.45434
P=0.02738
